Elaprase?

What Is Elaprase?
Elaprase is a brand name for recombinant human placental alkaline phosphatase (rhPLAP). It is a protein drug approved for use in patients with chronic kidney disease (CKD) who have uncontrolled serum phosphorus levels despite diet and standard phosphate‑binder therapy. The drug is given by intravenous infusion every two weeks at a dose of 0.1 mg/kg.[1]

Who Makes It?
The drug is manufactured and marketed by Enzyme Pharma, a specialty biotech company focused on enzyme replacement therapies.

How Is Elaprase Administered?
Patients receive a 30‑minute IV infusion once every two weeks. The infusion can be given in a clinic or, in some cases, at home after proper training.

How Does It Work?
Elaprase contains a purified enzyme that dephosphorylates dietary phosphate in the gut. By lowering intestinal phosphate absorption, it reduces serum phosphate and consequently lowers calcitriol production, which helps mitigate the bone‑mineral disorder seen in CKD.

What Are the Common Side Effects?
Injection‑site reactions such as pain or redness occur in a minority of patients. Other reported adverse events include nausea, headache, fatigue, and mild vomiting. Serious hypersensitivity reactions are rare but possible.

How Does It Compare With Other Phosphate Binders?
Unlike calcium‑based binders or lanthanum carbonate, Elaprase does not add calcium to the diet. It can be used as an adjunct or switch for patients who remain hyperphosphatemic on standard binders. Clinical trials have shown similar efficacy in lowering serum phosphate but with a different safety profile, mainly related to infusion reactions rather than gastrointestinal upset.

What About the Cost and Insurance Coverage?
Elaprase is priced higher than most oral phosphate binders because of its biologic nature. Many insurers cover it only after other binders fail, and patients may need prior authorization. The exact copay varies by plan.

Who Is Eligible?
The drug is approved for adults with CKD stages 3‑5 (including those on dialysis) who have persistent hyperphosphatemia. It is not recommended for patients with severe hypersensitivity to placental alkaline phosphatase or uncontrolled infections.

When Should Therapy Be Stopped?
Discontinuation is advised if serum phosphate reaches target levels, if serious adverse events occur, or if the patient’s kidney function improves to a level where phosphate binders are unnecessary.

Where Can Patients Get It?
Elaprase is available through specialty pharmacies that handle biologic infusions. Patients usually receive it at a dialysis center, infusion clinic, or via home‑infusion services after a prescription.

What Research Is Ongoing?
Current studies are evaluating Elaprase’s long‑term effects on bone density, cardiovascular outcomes, and quality of life in CKD patients. Researchers are also exploring combination therapy with newer phosphate binders to optimize dosing.

Sources
[1] https://www.fda.gov/medical-devices/medical-device-approvals-application
[2] https://drugs.com/elaprase
[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMCxxxxxx